ClinicaliQ Trial Snapshot
- A Study to Evaluate the Efficacy of NIO752 in Participants With Progressive Supranuclear Palsy — Recruiting • Phase III • NCT07498426.
- NIO752 is being tested to see if it can help slow progression of Progressive Supranuclear Palsy, a rare brain disorder affecting movement and balance.
Verify eligibility, endpoints and current status on the original ClinicalTrials.gov registry before acting on this summary.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
This Phase III study is intended to evaluate the efficacy and safety of NIO752 in participants with Progressive Supranuclear Palsy (PSP). Eligible participants will be randomized to receive either NIO752 or placebo followed by an open-label extension. Conditions: Progressive Supranuclear Palsy Richardson Syndrome (PSP-RS) Interventions: NIO752, Placebo Lead Sponsor: Novartis Pharmaceuticals Planned Enrollment: 300 participants